Skip to main content

Akeso

Akeso, Inc. is a Chinese biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative antibody therapeutics for oncology and autoimmune diseases. The company operates through an integrated biopharmaceutical research and commercialization model, utilizing its proprietary TETRABODY drug discovery platform. Its principal revenue drivers consist of commercial sales of proprietary bispecific and monoclonal antibody drugs, upfront licensing payments, and milestone royalties from global pharmaceutical partners. Akeso holds a prominent market position in China's biopharmaceutical sector as a pioneer in bispecific antibody treatments, having commercialized breakthrough immuno-oncology drugs including cadonilimab and ivonescimab. The enterprise focuses on developing next-generation bispecific antibodies, executing global clinical trials, advancing commercial manufacturing capacity, and establishing international commercial partnerships. Akeso, Inc. is headquartered in Zhongshan, Guangdong Province, China, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.

17 of the funds FundTelligence covers report a position in Akeso.

Legal name
Akeso Inc
Sector
Health Care
Country
China
Funds holding it
17

Funds holding Akeso

Showing the 8 largest of 17 funds holding it.

Loading...